Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances

The ongoing outbreak of the recently emerged 2019 novel coronavirus (nCoV), which has seriously threatened global health security, is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high morbidity and mortality. Despite the burden of the disease worldwide, still, no licensed vaccine or any specific drug against 2019-nCoV is available. Data from several countries show that few repurposed drugs using existing antiviral drugs have not (so far) been satisfactory and more recently were proven to be even highly toxic. These findings underline an urgent need for preventative and therapeutic interventions designed to target specific aspects of 2019-nCoV. Again the major factor in this urgency is that the process of data acquisition by physical experiment is time-consuming and expensive to obtain. Scientific simulations and more in-depth data analysis permit to validate or refute drug repurposing opportunities predicted via target similarity profiling to speed up the development of a new more effective anti-2019-nCoV therapy especially where in vitro and/or in vivo data are not yet available. In addition, several research programs are being developed, aiming at the exploration of vaccines to prevent and treat the 2019-nCoV. Computational-based technology has given us the tools to explore and identify potentially effective drug and/or vaccine candidates which can effectively shorten the time and reduce the operating cost. The aim of the present review is to address the available information on molecular determinants in disease pathobiology modules and define the computational approaches employed in systematic drug repositioning and vaccine development settings for SARS-CoV-2.     

Immunogenicity and protective efficacy of recombinant M2e.Hsp70c(Hsp70_(359–610)) fusion protein against influenza virus infection in mice

New strategies in vaccine development are urgently needed to combat emerging influenza viruses and to reduce the risk of pandemic disease surfacing. Being conserved, the M2 e protein, is a potential candidate for universal vaccine development against influenza A viruses. Mycobacterium tuberculosis Hsp70(mHsp70) is known to cultivate the function of immunogenic antigen-presenting cells, stimulate a strong cytotoxic T lymphocyte(CTL) response, and stop the induction of tolerance. Thus, in this study, a recombinant protein from the extracellular domain of influenza A virus matrix protein 2(M2e), was fused to the C-terminus of Mycobacterium tuberculosis Hsp70(Hsp70c), to generate a vaccine candidate. Humoral immune responses, IFN-γ-producing lymphocyte, and strong CTL activity were all induced to confirm the immunogenicity of M2 e.Hsp70c(Hsp70359–610). And challenge tests showed protection against H1N1 and H9N2 strains in vaccinated groups. Finally these results demonstrates M2 e.Hsp70c fusion protein can be a candidate for a universal influenza A vaccine.     

Metal-doped graphene layers composed with boron nitride–graphene as an insulator: a nano-capacitor

A new family of energetic azacubane N-oxides were designed by introducing N-oxides into azacubanes and investigated by using density functional theory. Introducing the N-oxides into the azacubanes could improve their detonation performance significantly due to the increase of the OB and ρ but would also increase the sensitivity to some extent. These effects would be further enhanced as the numbers of N-oxides increase. Among all the designed azacubane N-oxides, D6-4 (1,3,5,7-tetraazacubane-1,3,5,7-tetraoxides) has higher detonation performance than one famous high explosive HMX (1,3,5,7-tetranitro-1,3,5,7-tetrazocane) and lower sensitivity than one very insensitive explosive TNT (1-methyl-2,4,6-trinitrobenzene), suggesting that its overall performance is outstanding and may be considered as the potential candidate of insensitive high explosives. The internal small cage C-N skeleton of D6-4 is surrounded by the external big cage hydrogen bonds and this special double cage structure may be an important reason why it has low sensitivity.     

Effect of prebiotic mannan oligosaccharide on hematological and blood serum biochemical parameters of cultured juvenile great sturgeon (Huso huso Linnaeus, 1754)

The nutritional effects of prebiotic mannan oligosaccharide were evaluated using hematological and blood serum biochemical parameters in cultured juvenile great sturgeon (Huso huso). Fish were offered formulated diets containing two levels of prebiotic mannan oligosaccharide (2 and 4 g kg^?1); a basal diet with no prebiotics was used as control. The experiment lasted for 46 days. Blood samples were collected from the caudal veins of 18 apparently healthy fish (average weight 217.77 ± 29.8 g) at the end of the trial. No significant differences were found in the serum enzyme activity levels between treatments (P > 0.05). However, adding mannan oligosaccharide as a supplement to the basal diet resulted in significant differences in lymphocytes and eosinophils between the control and the 2 g kg^?1 treatment (P < 0.05) as well as a significant difference in the creatinine factor in the 2 g kg^?1 mannan oligosaccharide treatment (P < 0.05). The results show that it would be advantageous to add 2 g kg^?1 mannan oligosaccharide to the diets of juvenile great beluga sturgeon (Huso huso).     

Tragacanth-mediate synthesis of NiO nanosheets for cytotoxicity and photocatalytic degradation of organic dyes

Bioprocess and Biosystems Engineering - In this study, NiO nanosheets have been manufactured using a co-precipitation approach that involved the usage of nickel nitrate (Ni (NO3)2.6H2O) as the raw...